Stavudine (d4T, Zerit)
Friedland, G.; Dunkle, L.W.; Cross, A.P.
Advances in Experimental Medicine and Biology 394: 271-277
1996
ISSN/ISBN: 0065-2598 PMID: 8815691 Document Number: 459479
Document emailed within 1 workday
Related Documents
Scarsella, A.; Coodley, G.; Shalit, P.; Anderson, R.; Fisher, R.L.; Liao, Q.; Ross, L.L.; Hernandez, J.E. 2002: Stavudine-associated peripheral neuropathy in zidovudine-naïve patients: effect of stavudine exposure and antiretroviral experience Advances in Therapy 19(1): 1-8Saimot, A.G. 1997: Stavudine: current information Presse Medicale 26(11): 514-515
Gerstoft, J. 1998: Stavudine and lamivudine. two new nucleoside analogues efficient against HIV Ugeskrift for Laeger 160(4): 457-461
Cherry, C.L.; Affandi, J.S.; Imran, D.; Yunihastuti, E.; Smyth, K.; Vanar, S.; Kamarulzaman, A.; Price, P. 2009: Age and height predict neuropathy risk in patients with HIV prescribed stavudine Neurology 73(4): 315-320
Vorasayan, P.; Phanthumchinda, K. 2011: Lactic acidosis associated with severe neuromuscular weakness and stavudine therapy Journal of the Medical Association of Thailand 94(4): 501-504
Villalba, N.; Soriano, V.; Gómez-Cano, M.; Castilla, J.; Mas, A.; González-Lahoz, J. 1997: Short-term efficacy and safety of stavudine in pretreated HIV-infected patients Antiviral Therapy 2(3): 185-189
Affandi, J.S.; Price, P.; Imran, D.; Yunihastuti, E.; Djauzi, S.; Cherry, C.L. 2008: Can we predict neuropathy risk before stavudine prescription in a resource-limited setting? Aids Research and Human Retroviruses 24(10): 1281-1284
Monno, L.; Cargnel, A.; Soranzo, M.L.; Chirianni, A.; Ferraro, T.; Di Stefano, M.; Angarano, G. 1999: Comparison of once and twice daily dosing of didanosine in combination with stavudine for the treatment of HIV-1 infection. Ai 454-146 Team Antiviral Therapy 4(4): 195-202
Røge, B.T.; Katzenstein, T.L.; Obel, N.; Nielsen, H.; Kirk, O.; Pedersen, C.; Mathiesen, L.; Lundgren, J.; Gerstoft, J. 2003: K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine Antiviral Therapy 8(2): 173-182
Hemanth Kumar, A.K.; Ramachandran, G.; Rajasekaran, S.; Padmapriyadarsini, C.; Narendran, G.; Anitha, S.; Subramanyam, S.; Kumaraswami, V.; Swaminathan, S. 2009: Pharmacokinetics of lamivudine and stavudine in generic fixed-dose combinations in HIV-1 infected adults in India Indian Journal of Medical Research 130(4): 451-457
Menezes, C.N.; Maskew, M.; Sanne, I.; Crowther, N.J.; Raal, F.J. 2011: A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects Bmc Infectious Diseases 11: 244
Holguín, A.; Dietrich, U.; Immelmann, A.; Soriano, V. 1998: Genotypic and phenotypic resistance to stavudine after long-term monotherapy. BMS-020 Spanish Study Group Antiviral Therapy 3(3): 183-186
Palmer, M.; Chersich, M.; Moultrie, H.; Kuhn, L.; Fairlie, L.; Meyers, T. 2013: Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa Aids 27(5): 781-785
Raffi, F.; Reliquet, V.; Ferré, V.; Arvieux, C.; Hascoet, C.; Bellein, V.; Besnier, J.M.; Breux, J.P.; Garré, M.; May, T.; Molina, J.M.; Perré, P.; Raguin, G.; Rozenbaum, W.; Zucman, D. 2000: The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults Antiviral Therapy 5(4): 267-272
Pensi, T. 2007: Fixed dose combination of lamivudine, stavudine and nevirapine in the treatment of pediatric HIV infection: a preliminary report Indian pediatrics 44(7): 519-521
Getahun, A.; Tansuphasawadikul, S.; Desakorn, V.; Dhitavat, J.; Pitisuttithum, P. 2006: Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-vir) in advanced HIV infection Journal of the Medical Association of Thailand 89(9): 1472-1478
Idigbe, E.O.; Adewole, T.A.; Eisen, G.; Kanki, P.; Odunukwe, N.N.; Onwujekwe, D.I.; Audu, R.A.; Araoyinbo, I.D.; Onyewuche, J.I.; Salu, O.B.; Adedoyin, J.A.; Musa, A.Z. 2005: Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: a preliminary report on the Nigerian antiretroviral program Journal of Acquired Immune Deficiency Syndromes 40(1): 65-69
Kiertiburanakul, S.; Khongnorasat, S.; Rattanasiri, S.; Sungkanuparph, S. 2007: Efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) in Thai HIV-infected patients Journal of the Medical Association of Thailand 90(2): 237-243
Isaakidis, P.; Raguenaud, M-Eve.; Phe, T.; Khim, S.A.; Kuoch, S.; Khem, S.; Reid, T.; Arnould, L. 2008: Evaluation of a systematic substitution of zidovudine for stavudine-based HAART in a program setting in rural Cambodia Journal of Acquired Immune Deficiency Syndromes 49(1): 48-54
Viengchareun, S.; Caron, M.; Auclair, M.; Kim, M.J.; Frachon, P.; Capeau, J.; Lombès, M.; Lombès, A. 2007: Mitochondrial toxicity of indinavir, stavudine and zidovudine involves multiple cellular targets in white and brown adipocytes Antiviral Therapy 12(6): 919-929